ArticleOncoimmunology2015
Article in Oncoimmunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07422896 (A Phase I First-in-human Trial of Bvax), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed Glioblastoma
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- B cell-based therapy produces antibodies that inhibit glioblastoma growth.The Journal of clinical investigation · 2024Article
- Next-generation antigen-presenting cell immune therapeutics for gliomas.The Journal of clinical investigation · 2023Review
- Intruders or protectors - the multifaceted role of B cells in CNS disorders.Frontiers in cellular neuroscience · 2023Review
- The influence of anti-cancer therapies on lymphocyte subpopulations of lung cancer patients.Frontiers in immunology · 2023Article
- Role of B cells as antigen presenting cells.Frontiers in immunology · 2022Review
- Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance.Cancer metastasis reviews · 2021Review
- Inflammation and tumor progression: signaling pathways and targeted intervention.Signal transduction and targeted therapy · 2021Article
- B cells in lung cancer-not just a bystander cell: a literature review.Translational lung cancer research · 2021Review
- Activation of 4-1BBL+ B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma.The Journal of experimental medicine · 2021Article
- Review
- CD40-activated B cells induce anti-tumor immunity in vivo.Oncotarget · 2017Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There has been a growing interest in the use of B cells for cancer vaccines, since they have yielded promising results in preclinical animal models. Contrary to dendritic cells (DCs), we know little about the migration behavior of B cells
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.